secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2026-08-05T20:07:47+00:00
Accession:  0001193125-26-335073
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion Q2 net loss $8.3M, cash $35.2M; T1D C-peptide data positive
-------------------------------------------------------------------------

- Net loss of $8.3M for Q2 2026, down from $20.7M in Q2 2025; cash $35.2M as of June 30, 2026.
- Cash runway projected into Q2 2027.
- Phase II COVALENT-211 (T2D insulin-deficient) data expected Q1 2027; COVALENT-212 (T2D on GLP-1 RA) data expected Q2 2027.
- Phase I GLP-131 (BMF-650 obesity) initial 28-day weight reduction data expected Q3 2026.
- T1D data: 52% increase in mean C-peptide AUC at Week 12 with icovamenib 200 mg; planning Phase II trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526335073/0001193125-26-335073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312526335073/bmea-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer